Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

被引：0
|
作者：
M. R. McClung
P. D. Miller
J. P. Brown
J. Zanchetta
M. A. Bolognese
C. L. Benhamou
A. Balske
D. E. Burgio
J. Sarley
L. K. McCullough
R. R. Recker
机构：
[1] Oregon Osteoporosis Center,
[2] Colorado Center for Bone Research,undefined
[3] Groupe de recherche en rhumatologie et maladies osseuses,undefined
[4] University of El Salvador,undefined
[5] Metabolic Research Institute,undefined
[6] Bethesda Health Research,undefined
[7] Institut de Prévention et de Recherche sur l’Ostéoporose,undefined
[8] Abbott Laboratories,undefined
[9] Procter and Gamble Pharmaceuticals,undefined
[10] The Procter and Gamble Company,undefined
[11] Warner Chilcott Pharmaceuticals Inc,undefined
[12] Ben Venue Laboratories,undefined
[13] ICON Clinical Research,undefined
[14] Creighton University,undefined
[15] Osteoporosis Research Center,undefined
来源：
Osteoporosis International | 2012年 / 23卷
关键词：
Bone mineral density; Delayed-release; Enteric-coated; Fracture risk; Osteoporosis; Risedronate; Weekly;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 276
页数：9
相关论文
共 50 条
  • [1] Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
    McClung, M. R.
    Miller, P. D.
    Brown, J. P.
    Zanchetta, J.
    Bolognese, M. A.
    Benhamou, C. L.
    Balske, A.
    Burgio, D. E.
    Sarley, J.
    McCullough, L. K.
    Recker, R. R.
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 (01) : 267 - 276
  • [2] EFFECT OF A DELAYED-RELEASE RISEDRONATE 35 MG ONCE-A-WEEK FORMULATION TAKEN WITH OR WITHOUT BREAKFAST ON BMD
    McClung, M. R.
    Zanchetta, J. R.
    Benhamou, C. L.
    Balske, A.
    Sarley, J.
    Recker, R. R.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : 25 - 25
  • [3] A NOVEL DELAYED-RELEASE RISEDRONATE 35 MG ONCE-A-WEEK FORMULATION TAKEN WITH OR WITHOUT BREAKFAST: 2-YEAR BMD DATA
    Benhamou, Claude-Laurent
    Zanchetta, Jose
    Kaufman, Jean-Marc
    Brown, Jacques
    Maasalu, Katre
    Lakatos, Peter
    Badurski, Janusz
    Wenderoth, Dietrich
    McClung, Michael
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 337 - 338
  • [4] Once-a-week (35 mg) risedronate is as effective as daily (5 mg)
    Lindsay, R
    Adachi, JD
    Emkey, RD
    Li, Z
    Balske, A
    Brown, J
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S16 - S16
  • [5] Two year vertebral fracture risk reduction with risedronate 35 mg once-a-week
    Watts, NB
    Lindsay, R
    Li, Z
    Kasibhatla, C
    Brown, J
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 : S36 - S36
  • [6] Vertebral fracture risk reduction over two years with risedronate 35 mg once-a-week
    Watts, NB
    Lindsay, R
    Li, Z
    Brown, J
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S40 - S40
  • [7] Efficacy of once-a-week risedronate in reducing vertebral fracture risk
    Watts, NB
    Li, Z
    Hoseyni, MS
    Seeman, E
    Lindsay, R
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 : S17 - S18
  • [8] Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
    McClung, M. R.
    Balske, A.
    Burgio, D. E.
    Wenderoth, D.
    Recker, R. R.
    OSTEOPOROSIS INTERNATIONAL, 2013, 24 (01) : 301 - 310
  • [9] Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
    M. R. McClung
    A. Balske
    D. E. Burgio
    D. Wenderoth
    R. R. Recker
    Osteoporosis International, 2013, 24 : 301 - 310
  • [10] Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate
    Watts, NB
    Lindsay, R
    Li, ZQ
    Kasibhatla, C
    Brown, J
    OSTEOPOROSIS INTERNATIONAL, 2003, 14 (05) : 437 - 441
12345